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The function of serotonin within the liverq
Richard G. Ruddell1,*, Derek A. Mann2, Grant A. Ramm1
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2Liver Group, Institute of Cellular Medicine, University of Newcastle, Newcastle upon Tyne NE2 4HH, UKSerotonin or 5-hydroxytryptamine (5-HT) is known to regulate several key aspects of liver biology and these functions
include hepatic blood ﬂow, innervation and wound healing. Given the importance of these functions it is surprising that
relatively little time has been dedicated to studying the precise function and mechanisms of serotonin within the liver. Here
we describe what is known about serotonin and the liver and those receptor types that mediate the observed eﬀects with an
aim to stimulating new interest in the ﬁeld of serotonin and liver biology.
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Serotonin also known as 5-hydroxytryptamine (5-
HT) is a biogenic amine that functions as a ligand for
a large family of 5-HT receptors [1]. The majority of
serotonin in the body (90%) is synthesised by entero-
chromaﬃn cells of the gastrointestinal (GI) tract and
from here it is exported to various sites around the body.
Serotonin plays a major role in neurotransmission
within the central nervous system (CNS) and the auto-
nomic nervous system (ANS). It is often the expression
patterns of the various serotonin receptors within the
CNS and ANS that determine the systems controlled
by serotonin. In the CNS serotonin is known to control0168-8278/$34.00  2008 European Association for the Study of the Liver.
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vein; SSRI, selective serotonin reuptake inhibitor.mood, behaviour, learning, sleep and anxiety to name
but a few. Peripherally, serotonin is able to mediate
vascular contraction and relaxation, gastrointestinal
motility, cell proliferation, apoptosis and platelet aggre-
gation. Serotonin is actively taken up by cells expressing
the Na+/Cl dependent serotonin transporter (SERT)
where it is stored in intracellular vesicles and released
in response to various stimuli. Once bound to target
receptors or taken up by the SERT, internalised seroto-
nin can be metabolised by monoamine oxidase (MAO)
leading to the generation of 5-hydroxyindoleacetalde-
hyde (5-HIAA). Concentrations of 5-HIAA can be
readily measured in the urine and are often used to
detect changes in whole body serotonin levels [2].
Fig. 1 gives an overview of the intermediate compounds
and enzymes involved in serotonin synthesis and metab-
olism. The family of receptors that bind serotonin is
subdivided into seven subgroups and where appropriate
these subgroups are again divided. Table 1 summarises
the characteristics associated with each member of the
human serotonin receptor family. These receptors have
been grouped according to their genetic and structural
similarities and also according to the intracellular
signalling pathways associated with each receptor. All
members of the serotonin receptor family are linked to
G-proteins, except the 5-HT3 receptor which is a ligand
gated Na+/K+ channel. The authors direct any readersPublished by Elsevier B.V. All rights reserved.
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Fig. 1. Serotonin synthesis and metabolism. The majority of whole body serotonin is synthesised from tryptophan by enterochromaﬃn cells in the
gastrointestinal tract and exported around the body. The liver is known to be an important site of serotonin metabolism leading to the generation of
breakdown products such as 5-hydroxyindoleacetaldehyde (5-HIAA). Outlined in this ﬁgure are the biochemical pathways that lead to the anabolism and
catabolism of serotonin and also the pathways of storage and cellular uptake. AADC, aromatic amino acid decarboxylase; AD (NAD), NAD-dependent
aldehyde dehydrogenase; MAO, monoamine oxidase; OH-THB, hydroxytetrahydrobiopterin; TH, tryptophan hydroxylase; THB, tetrahydrobiopterin.
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receptor families and their associated signalling path-
ways to the review by Raymond and colleagues [3].
A considerable array of speciﬁc/non-speciﬁc agonists
and antagonists exists that allows the researcher to tar-
get serotonin receptors expressed by cells in speciﬁc tis-
sues/organs either in healthy individuals or in various
disease conditions. Many of these compounds are also
able to bind to a number of other receptor types (for
example, dopaminergic, adrenergic and cholinergic)
and are thus described as ‘‘dirty compounds”. The list
of extra-hepatic diseases that involve a role for serotonin
is large, but they can be divided into diseases that mainly
aﬀect brain or peripheral function. The most clinically
important diseases of the brain where serotonin has
been implicated include migraine [4], depression [5],
schizophrenia [6] and Alzheimer’s disease [7]. Perhaps
the most clinically important peripheral diseases associ-
ated with serotonin are cardiovascular disease [8] and
GI disorders such as irritable bowel syndrome [9]. The
oﬀ-target eﬀects of compounds used to treat these disor-ders are as complex as the disease they are used to treat,
but can include akathisia, insomnia, seizure, anxiety,
low blood pressure and sexual dysfunction.
This review, however, will focus on what is known
about the basic functions of serotonin within the liver,
on the vessels supplying the liver with blood and within
the nerve connections that regulate liver function. The
review will also focus on the translational and clinical
aspects of serotonin biology in terms of pathophysiol-
ogy and the therapeutic applications of serotonin and
relevant antagonists in human liver disease (summarised
in Fig. 2).2. Serotonergic innervation of the liver
2.1. Experimental evidence
Both the sympathetic [10] and parasympathetic [11]
branches of the autonomic nervous system are known
to regulate several human hepatic metabolic functions
Table 1
Summary of human 5-HT receptor characteristics
Human receptor Agonists Antagonists G protein
coupling
Common signalling
linkage
Functions
5-HT1A 8-OH-DPAT, buspirone,
5-CT
WAY 100635,
methiothepin, spiperone
Gi/o Inhibits AC Activates
K+ channels Stimulates
ERK
CNS: neuronal hyperpolarisation
5-HT1B 5-CT, CP 93129,
sumatriptan
SDZ 21009,
methiothepin, yohimbine
Gi/o Inhibits AC Stimulates
ERK
CNS: inhibition of
neurotransmitter release
5-HT1D Sumatriptan, L 694247,
5-CT
Metergoline,
methiothepin, GR
127935
Gi/o Inhibits AC CNS: inhibition of
neurotransmitter release
5-HT1E 5-HT Methiothepin Gi/o Inhibits AC Not yet characterised
5-HT1F 5-HT Methiothepin Gi/o Inhibits AC Not yet characterised
5-HT2A a-Methyl-5-HT, DOI Ketanserin, ritanserin,
pirenperone
Gq Activates PLC & PKC
Stimulates ERK
Activates PLA2
CNS: neuronal excitation
Periphery: smooth muscle
contraction, platelet aggregation
5-HT2B a-Methyl-5-HT, DOI SB 200646, LY 53857 Gq Similar to 5-HT2A Periphery: GI motility
5-HT2C a-Methyl-5-HT, DOI Mesulergine, ritanserin,
LY 53857
Gq Similar to 5-HT2A CNS: cerebrospinal ﬂuid
secretion.
5-HT3 2-Methyl-5-HT,
m-chlorophenyl-
biguanide
Ondansetron,
tropisetron
N/A Peripheral and central neurons:
depolarisation
5-HT4 Metoclopramide,
renzapride
GR 113808, SB 204070,
tropisetron
Gs Activates AC & PKA CNS: neuronal excitation
Periphery: GI tract motility,
tachycardia
5-HT5A 5-HT, 5-CT Methiothepin Unknown Unknown Not yet characterised
5-HT5B 5-HT Methiothepin Unknown Unknown Not yet characterised
5-HT6 5-HT, LSD SB 271046 Gs Activates AC & PKA CNS: unknown
5-HT7 5-HT, LSD, 5-CT Methiothepin Gs Activates AC & PKA CNS: unknown Periphery:
unknown
5-CT, 5-carboxamidotryptamine; 5-HT, 5-hydroxytryptamine; 8-OH-DPAT, 8-hydroxy-2-di-n-propylamino-tetralin; AC, adenylate cyclase; CNS,
central nervous system; DOI (±)-([1-(2,5-Dimethoxy-4-iodophenyl)-aminopropane]-hydrochloride); ERK, extracellular regulated kinase; GI, gas-
trointestinal; LSD, lysergic acid diethylamide; PKA, protein kinase A; PKC, protein kinase C; PLA, phospholipase A; PLC, phospholipase C.
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tonergic nerve ﬁbres are included in the peptidergic
family of the ANS and have been previously shown
in man to be localised to the tunica media on
branches of the hepatic artery and portal vein as well
as bile ducts and the connective tissue of the interlob-
ular septa [13]. In addition the presence of serotonin
positive nerve ﬁbres in portal tracts and that of
ﬁbrous septa within rat hepatic lobules have also been
demonstrated [14].
Recent experimental work has shown an increase in
5-HT2C receptor expression in the brain stem and
cerebral cortex during liver regeneration following
partial hepatectomy (PHx) and N-nitrosodiethyl-
amine-triggered hepatic neoplasia in rats. Brain stem
serotonin was also signiﬁcantly elevated in rats follow-
ing both PHx and N-nitrosodiethylamine treatment
[15]. In addition spontaneously hypertensive Wistar–
Kyoto rats subjected to CCl4 treatment, also demon-
strate a signiﬁcant increase and rearrangement of both
serotonin particles and mast cells (a source of seroto-
nin) within the ﬁbrous septum of the repairing liver
[12].2.2. Serotonergic innervation of the human liver
The importance of serotonergic innervation to
human liver regeneration remains relatively unexplored.
Experimental animal data and preliminary experiments
in human liver show the presence of serotonergic neu-
rons would suggest it does have a role. The exact recep-
tor subtypes that are found on nerve tissue within the
human liver are an enigma. However, the availability
of serotonin agonists which can speciﬁcally bind to var-
ious members of the serotonin receptor family presents
the researcher with the possibility that serotonergic
innervation of the liver can be modulated with resultant
beneﬁcial eﬀects on regeneration.3. Serotonin and the hepatic vasculature
The ability of serotonin to regulate blood ﬂow and
vascular tone has been known since 1868, however, it
was not until 1948 that serotonin was isolated and char-
acterised [16]. This led to the logical question– can sero-
tonin also regulate the ﬂow of blood within the liver?
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Flow: 5-HT2Biliary Tree
Growth: 5-HT1B
ANS Mediated
Hepatic Regeneration:
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Hepatocyte &
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Fig. 2. A summary of the major liver processes inﬂuenced by serotonin
and the proposed receptors that mediate those events. 5-HT, 5-
hydroxytryptamine; HSC, hepatic stellate cell.
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receptor family on hepatic blood ﬂow and other aspects
of vascular function have been studied in both animal
models of liver disease and in humans. What is known
about the ability of serotonin to regulate hepatic blood
ﬂow at both the portal and sinusoidal levels, and also
the various experimental attempts to regulate normal
and diseased hepatic blood ﬂow will be discussed.
3.1. Experimental regulation of portal blood ﬂow by
serotonin
Preliminary experiments have shown an increase in
portal resistance elicited by serotonin in normal healthy
dogs [17]. Subsequent experiments performed by Cum-
mings and colleagues further deﬁned the role of seroto-
nin in regulating rat portal venous pressure. Their data
demonstrated that the isolated superior mesenteric vein
(SMV) of portal hypertensive rats was signiﬁcantly more
sensitive to serotonin administration than non-hyperten-
sive rats [18]. The eﬀects of serotonin on the isolated
SMV were blocked by the known 5-HT2 receptor
antagonist, ketanserin, suggesting the involvement of
the 5-HT2 receptor. Similarly intraportal injections of
serotonin were found to signiﬁcantly increase portalpressure, events that were antagonised by ketanserin in
portal hypertensive rats but not normal rats. The eﬀects
of ketanserin were found to be due to a decrease in por-
tal inﬂow which followed a decrease in cardiac output,
consistent with venous dilation and pooling of blood
within the portal system, leading to the proposition that
ketanserin should be explored for the treatment of
patients with portal hypertension [18].
Both a and b adrenoceptors are also known to regu-
late portal pressure [19] which is important when one
considers that ketanserin also has a lower aﬃnity for
the a1-adrenoceptor [20]. Experiments that compared
and contrasted the actions of prazosin (a1-adrenoceptor
antagonist) and ketanserin demonstrated that a1-adre-
noceptor blockade had no eﬀect on the portal pressure
of hypertensive rats [20]. Other studies have investigated
the role of the selective 5-HT2 antagonist ritanserin in
reducing portal pressure in experimentally hypertensive
rats with [21] or without [22] cirrhosis and in dogs with
portal hypertension and cirrhosis [23]. In all cases signif-
icant reductions in hepatic portal vein pressures were
achieved without causing systemic haemodynamic
changes.
3.2. Experimental regulation of sinusoidal blood ﬂow by
serotonin
Various studies have also investigated the eﬀects of
serotonin and the 5-HT2 receptor antagonist LY53857
on the blood ﬂow of the hepatic sinusoid. Reduced ﬂow
at the inlet of the periportal and outlet of the centrive-
nous sinusoids induced by serotonin was completely
antagonised by 1 mg/kg LY53857 [24]. It could be con-
cluded that 5-HT2 receptors were localised on hepatic
sinusoids and that it was this subtype of receptor that
mediated the hypoperfusion of the hepatic sinusoid elic-
ited by serotonin [24]. One resident of the hepatic sinu-
soid that is postulated to regulate blood ﬂow is the
hepatic stellate cell (HSC). The HSC is known to
undergo an activation process acquiring a smooth mus-
cle cell-like phenotype with enhanced contractile capa-
bilities in response to liver injury. The HSC has
recently been demonstrated to express functional 5-
HT2A and 5-HT2B receptors [25] and it is therefore pos-
sible that the HSC is able to regulate sinusoidal blood
ﬂow. Contrary to this hypothesis experimental data
from Rockey and colleagues failed to demonstrate cellu-
lar contraction of HSC invoked by serotonin on colla-
gen lattices [26]. However, it should be noted that the
HSCs in these experiments were activated and therefore
a role for quiescent HSC in regulating sinusoidal blood
ﬂow cannot be ruled out.
Sinusoidal endothelial cells (SECs) are also known
to respond to serotonin incubation [27,28]. Serotonin
is able to induce the contraction of fenestrae which
is achieved via a rapid inﬂux of extracellular Ca2+
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these cells serotonin also inhibits cAMP production,
and activates phospholipase A2, causing the release
of arachidonic acid [28]. The exact signiﬁcance of
these ﬁndings has not been fully qualiﬁed, it is, how-
ever, well established that SEC fenestrae play an
important role in the exchange of ﬂuid, solutes and
particles between the parenchyma and the blood.
Serotonin may therefore play a role in regulating the
exchange of various ﬂuids, solutes and particles across
the space of Disse. Serotonin in these cells may also
exert complex control over various aspects of inﬂam-
mation and immunity since arachidonic acid is a pre-
cursor of various prostaglandins, prostacyclin, and
thromboxane.
3.3. Role of serotonin in human hepatic vasculature
A number of studies have demonstrated the respon-
siveness of the human hepatic vasculature to serotonin
and the 5-HT2 antagonist ketanserin [29–32]. Seroto-
nin is known to stimulate the contraction of the
human hepatic artery and in patients with liver cirrho-
sis this contractility is moderately enhanced [31].
Administration of 10 mg i.v. ketanserin to cirrhotic
patients was found to decrease mean arterial pressure,
the hepatic venous pressure gradient and azygos blood
ﬂow, with hepatic blood ﬂow remaining unchanged
[29]. These ﬁndings would suggest that serotonergic
mechanisms may contribute to maintaining portal
hypertension in patients with cirrhosis [29]. The role
of b-adrenergic blockade (propranolol) in conjunction
with serotonergic blockade (ketanserin) in patients
with alcoholic cirrhosis has also been deﬁned [30].
Results demonstrated an independent and additive
decrease in wedged hepatic venous pressure, hepatic
venous pressure gradient and azygos blood ﬂow [30].
Investigations into the beneﬁts of long-term treatment
using a 5-HT2 receptor antagonist (51 mg ketanserin
per day for 32 days) on patients with portal hyperten-
sion also demonstrated a signiﬁcant decrease in portal
pressure. However, 50% of patients in the study devel-
oped signiﬁcant side eﬀects which included reversible
portosystemic encephalopathy [32]. The frequency of
the side eﬀects ruled out further investigations into
the beneﬁcial eﬀects of 5-HT2 receptor antagonism
on portal hypertension at least until the development
of more selective agents.
3.4. Altered peripheral serotonin and platelet function in
patients with cirrhosis
Patients with advanced liver disease often present
with variceal haemorrhage and a more generalised
‘‘bleeding tendency” [33]. These additional symptoms
linked to hepatic cirrhosis are thought in part to bedue to impaired platelet aggregation, with deﬁciencies
identiﬁed in several aggregating agents in the platelet-
rich plasma of cirrhotic patients [33]. Under normal
conditions platelets are activated in response to a
variety of diﬀerent stimuli, releasing various aggregat-
ing factors including serotonin, and following this
they become exhausted. Patients with cirrhosis are
known to have signiﬁcantly lower peripheral blood
serotonin and intraplatelet serotonin concentrations
when compared to healthy individuals [34]. Platelet
storage pool defects have been shown in cirrhotic
patients which prevent the storage of a number of
factors including serotonin [33]. It is therefore tempt-
ing to propose that the reduced blood serotonin con-
centration and platelet serotonin storage ability were
in part responsible for the haemorrhagic tendency
of cirrhotic patients. The reasons for the decreased
intraplatelet and peripheral blood serotonin levels in
patients with cirrhosis are unclear. A number of stud-
ies have now described a role for platelet serotonin in
mediating hepatic regeneration. Whether this leads to
depleted platelet serotonin remains to be determined,
it has, however, been suggested that these ﬁndings
might justify platelet transfusion in patients with
low platelet counts when they bleed spontaneously
or before undergoing surgery or liver biopsy [35].
To date no controlled clinical trials have been per-
formed to test this hypothesis.4. Serotonin and hepatic wound healing
The liver demonstrates a remarkable capacity for
regeneration and following 70% PHx in rodents is able
to almost completely restore its lost mass within 14 days
[36]. The hepatic regenerative and wound healing pro-
cesses are tightly regulated and known to involve many
hepatic and extra-hepatic cell types. While much work
has been done in understanding rodent liver regenera-
tion and its response to injury many important ques-
tions regarding human liver regeneration remain
unanswered. The concept that serotonin may play a role
in hepatic regeneration is gaining interest with several
recent papers highlighting the importance of serotonin
in rodent hepatic wound healing. The hypothesised
events mediated by various cell types in response to
serotonin at the sinusoidal level are summarised in
Fig. 3 and Table 2. With the development of a consider-
able array of knockout mice lacking speciﬁc serotonin
receptors and the SERT, new opportunities exist to fur-
ther study the role of speciﬁc components of the seroto-
nin signalling cascade within the normal and diseased
liver. Armed with this knowledge, translational research
into the mechanisms that underlie human liver regener-
ation following injury may lead to new and novel thera-
peutic targets.
Hepatocyte
5-HT2A?
SERT 5-HT?
5-HT2A/B
CTGF
5-HT1?
5-HT
5-HT
Receptor
Platelet
Space of Diss e
HSC
Proliferation
Proliferation
Activation
Apoptosis
Fenestrae
Contraction
5-HT? Hepatic
Regeneration
Sinusoid
constriction
AlteredEndothelial Cell
blood flow
Ca2+
GDP
GTP
?
?
G
D
P
G
TP
? ?
5-HT2A? 5-HT?
GDP
GTP
?
?
?
Fig. 3. Known and hypothesised functions of serotonin on cells of the hepatic sinusoid. Contraction of sinusoidal endothelial cell fenestrae is triggered by
serotonin in a Ca2+ dependant manner. Simultaneous inhibition of cAMP production in these cells would suggest that a serotonin receptor subtype
(possibly 5-HT1) negatively coupled to adenylate cyclase may be mediating the observed changes. Platelets are known to be the major source of sinusoidal
serotonin in times of liver injury and have also been shown to adhere to sinusoidal endothelial cells and also to translocate to the space of Disse in response
to various proinﬂammatory mediators where serotonin mobilisation occurs. Serotonin within the space of Disse is then free to bind serotonin receptors
expressed by both quiescent and activated HSC as well as hepatocytes. In response to serotonin both cell types are known to proliferate and experimental
data indicate that serotonin is able to prevent HSC apoptosis and regulate gene expression. HSCs are also able to traﬃc serotonin to an internal
compartment from which it can be released thereby initiating a possible feedback loop sustaining both hepatocyte and activated HSC proliferation. Both
cell types are known to contribute to the regeneration of hepatic mass following liver injury. Serotonin has also been shown to regulate sinusoidal blood
ﬂow. The fact that both endothelial cells and HSC express serotonin receptors and are contractile gives rise to the possibility that both cell types can
regulate sinusoidal blood ﬂow in response to serotonin. Red arrows represent plausible but as-yet untested pathways. 5-HT, 5-hydroxytryptamine; CTGF,
connective tissue growth factor; GDP, guanosine diphosphate; GTP, guanosine triphosphate: HSC, hepatic stellate cell; SERT, serotonin transporter.
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is by no means new information, with many studies in
existence from at least the early 1980s. However, these
publications were often not originally published in Eng-
lish and were diﬃcult to obtain until quite recently, thus
keeping them relatively unknown.Table 2
Outline of the cell-speciﬁc expression of various components of the 5-HT depe
Cell type 5-HT components expressed
Hepatocyte 5-HT2A, SERT, MAO
Bile duct epithelial cell 5-HT1A, 5-HT1B, SERT
Hepatic stellate cell 5-HT1B, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT7, SER
Endothelial cell Unknown
SERT, serotonin transporter; MAO, monoamine oxidase; 5-HT, 5-hydroxyt4.1. In vivo studies investigating the role of serotonin in
hepatic regeneration
Kulinskii and colleagues were the ﬁrst to describe
the eﬀects of serotonin and various serotonin
antagonists on mouse liver regeneration followingndent signalling pathways and those functions regulated
Functions
Proliferation, oxidant stress, mitochondrial toxicity
Proliferation, biliary tree growth
T Proliferation, growth factor expression, apoptosis, contraction?
Fenestra contraction
yrptamine.
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serotonin and accumulation in the liver and spleen fol-
lowing PHx [39]. Subsequent work showed enhanced
hepatocyte proliferation following low-dose adminis-
tration of serotonin also to mice subjected to PHx
[38]. The role of serotonin agonists, 5-methoxytrypta-
mine and a-naphthylbiguanide (a 5-HT3 receptor
agonist) and that of the antagonist Lisuride on regen-
eration following PHx were also investigated. 5-meth-
oxytryptamine was found to mimic serotonin and the
eﬀects of serotonin were blocked by Lisuride which is
known to antagonise the 5-HT1A/1B and 5-HT2B recep-
tors whereas a-naphthylbiguanide had no eﬀect. Subse-
quent work demonstrated that serotonin was able to
elevate cAMP and cGMP within rat hepatocytes
exposed to X irradiation and cycloheximide [40] and
also enhance hepatic poly-(A) RNA synthesis in
normal healthy Wistar rats [41]. It should be noted that
these early studies into the eﬀects of serotonin on
liver regeneration were done at a time with limited
availability of speciﬁc pharmacological agents and
incomplete knowledge of serotonin receptor biology.
More recently a number of studies have reinvesti-
gated the role of serotonin, however, this time against
a background of knockout technology, advances in
serotonin receptor ligand design and advances in recep-
tor characterisation. [42–44]. Ketanserin is now known
to be a potent inhibitor of liver regeneration and more
speciﬁcally hepatocyte proliferation following PHx
[43]. Hepatic stimulator substance, which is known to
be a potent hepatocyte growth factor, is also unable to
overcome the blockade of liver regeneration by ketan-
serin following PHx [44]. Recent elegant studies by
Lesurtel et al. identiﬁed platelets as the major source
of serotonin that drives liver regeneration in PHx mice
[42]. They found that liver regeneration in thrombocyto-
penic mice following PHx was restored by supplement-
ing the mice with platelet-rich plasma containing near
WT levels of serotonin [42]. These eﬀects were mimicked
by the 5-HT2 agonist 2,5-dimethoxy-4-iodoamphet-
amine (DOI) and antagonised by ketanserin and to a les-
ser degree SB 206553 (5-HT2B/2C receptor antagonist).
These results again suggest a key role for the 5-HT2 fam-
ily of receptors in mediating hepatic regeneration.
4.2. In vitro studies investigating the role of serotonin in
hepatic regeneration
Similarly advances in serotonin receptor cloning
and characterisation in conjunction with the develop-
ment of serotonin receptor ligand-binding proﬁles
allowed for more detailed studies of serotonin recep-
tors expressed by hepatocytes in vitro. Balasubramani-
an and Paulose were the ﬁrst to publish data on the
stimulation of DNA synthesis in hepatocytes by one
of the 5-HT2 receptor family members [45]. Using pri-mary rat hepatocytes Balasubramanian and Paulose
showed serotonin was able to induce a dose-dependent
increase in [3H]thymidine incorporation into DNA in
the presence of epidermal growth factor and insulin
[45]. The 5-HT2 antagonists ketanserin and spiperone
were able to displace [3H]serotonin binding from crude
liver-membrane preparations and also inhibit the stim-
ulatory eﬀects of serotonin on hepatocyte DNA syn-
thesis [45]. It should be noted that these experiments
were performed at a time when 5-HT2 receptor biol-
ogy was in its infancy and the existence of three sep-
arate members of the 5-HT2 was unknown. Today the
three members of the 5-HT2 family have been fully
characterised and armed with this knowledge new
insight into the exact function and expression patterns
of the 5-HT2 receptor family on hepatocytes can be
more fully explored.
4.3. Serotonin and the hepatic stellate cell
As previously mentioned the HSC is an important
component in the response of the liver to injury in
terms of both wound healing and scar formation in
cases of extended liver insult. Interestingly, activation
of the HSC has also been demonstrated in response
to PHx in rats [36]. This ﬁnding indicates that HSC
activation is not only important in examples of
extended liver injury but also in hepatic regeneration
with little or no ﬁbrosis present. Serotonin is now
known to regulate several key facets of HSC biology
with regard to their involvement in wound healing
[25]. Five members of the serotonin receptor family
have been identiﬁed in HSC including 5-HT1B, 5-
HT1F, 5-HT2A, 5-HT2B and 5-HT7 receptors. It has
been demonstrated that both the 5-HT2A and 5-
HT2B receptors are upregulated (100- and 50-fold,
respectively, that of quiescent HSC) in response to
activation, suggesting an important role for these
receptors in the function of the HSC. In the presence
of PDGF-BB, serotonin was able to stimulate HSC
proliferation. While on its own it was able to induce
CTGF expression and protect HSC against nerve
growth factor-induced apoptosis. An array of 5-HT2
antagonists was also found to inhibit HSC prolifera-
tion and stimulate apoptosis and in addition activated
HSCs also expressed the SERT and were able to inter-
nalise serotonin [25]. Considering the locality of the
HSC in the liver, these ﬁndings take on added signif-
icance with the knowledge that the proinﬂammatory
cytokines TNFa, IL-1 and LPS are known to induce
translocation of platelets to the space of Disse in mice
where serotonin mobilisation occurs [46]. This may
represent an important mechanism by which the
HSC gains access to serotonin in response to injury,
thus allowing serotonin to modulate the behaviour
of the HSC.
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Serotonin has been proven to regulate biliary tree
growth via the 5-HT1A and 5-HT1B receptors in the
rat bile duct-ligated rat model of cholestasis [47]. Bile
duct epithelial cell (BDEC) proliferation is markedly
inhibited by agonist activation of the 5-HT1A (8-OH-
DPAT) and 5-HT1B (anpirtoline). Marzioni and col-
leagues also showed that BDECs were able to secrete
serotonin in much the same manner as HSCs and the
authors postulated the existence of self governing BDEC
antiproliferative loop regulated by serotonin [47]. Selec-
tive serotonin reuptake inhibitors (SSRI) such as citalo-
pam and paroxetine have been linked with cholestasis in
addition to severe acute and chronic hepatitis in humans
[48–50]. The mechanisms by which SSRI contribute to
cholestasis are unknown and occurrences are very rare.
When one considers that BDECs express the 5-HT1A
and 5-HT1B receptors in addition to the SERT, it is pos-
sible that serotonin may regulate bile excretion and
SSRI treatment may disrupt this pathway in predis-
posed patients.
4.5. Deleterious eﬀects of serotonin on hepatic
regeneration
Serotonin does not always play a beneﬁcial role in
liver regeneration following injury. Indeed two animal
studies have shown serotonin contributes to liver injury
and hypoperfusion following ischaemia and reperfusion
of the small intestine [51] and the liver [52]. Both models
of ischaemia resulted in elevated serotonin levels in the
portal and hepatic veins resulting in decreased hepatic
blood ﬂow and hepatic microcirculation injury, with evi-
dence suggesting that serotonin was derived from plate-
lets [52]. Conversely, platelet-derived serotonin has been
shown to be beneﬁcial in terms of stimulating hepato-
cyte proliferation following hepatic ischaemia in mice
[53]. In addition over proliferation by hepatocytes can
lead to hepatocellular carcinoma (HCC) and this would
raise the possibility that serotonin may play a role in
HCC, although to date this hypothesis has remained
untested.
4.6. Studies on the role of serotonin in human liver disease
Serotonin breakdown catalysed by monoamine oxi-
dase (MAO; see Fig. 1) is known to generate hydrogen
peroxide [54]. In examples of experimentally induced
NASH serotonin has been shown to elevate oxidative
stress and contribute to mitochondrial damage via ele-
vated expression of both the SERT and MAO [55].
MAO is known to be elevated in patients with NASH,
suggesting serotonin may play a clinically relevant role
in disease progression in humans [55].4.7. Summary
Current data clearly indicate the importance of sero-
tonin in mediating various facets of hepatic regenera-
tion. The overwhelming majority of data suggest that
serotonin acting mainly through the 5-HT2A and 5-
HT2B receptors plays a key role in mediating hepatocyte
proliferation and restoration of hepatic mass following
injury. HSC activation is an important part of the hepa-
tic response to injury and is as important to the regener-
ative arm of this response as it is to the ﬁbrotic arm.
Fig. 3 outlines known and hypothesised roles for seroto-
nin acting at the sinusoidal level on three separate cell
types. Much more information is required to fully com-
plete this picture and the existence of other serotonin
receptor subtypes on hepatocytes, SEC and HSC, can-
not be ruled out. To date no attempts have been made
to investigate either serotonin receptor expression or
the role of serotonin in human hepatic regeneration
and recovery from liver injury. Numerous studies aimed
at resolving experimentally induced ﬁbrosis in various
animal models of hepatic injury have been performed.
Equally, a large number of studies indicate that once
the underlying causes of liver injury are treated in either
humans or animals spontaneous resolution of ﬁbrosis
can occur. The eﬀects of serotonin on the liver represent
another possible point of intervention whereby the
return of the liver to a normal healthy state can be
enhanced.5. Conclusion
It is apparent that serotonin plays a crucial role in
regulating hepatic function and response to injury.
Acting as a neurotransmitter and as a neuroendocrine
hormone, it regulates ANS input to the liver, blood
ﬂow within the normal and healthy liver and also reg-
ulates the proliferation and function of a number of
key resident liver cells (as can be seen in Table 2).
The ability of serotonin to modulate all of these fac-
tors renders it crucial in times of hepatic injury and
repair. Data are very limited regarding the function
of serotonin within the human liver and this review
represents the ﬁrst comprehensive attempt to bring
all of this information together. Due to the availability
of a number of selective agonists and antagonists for
the various serotonin receptor subtypes (some of
which were covered here) and knockout mice lacking
speciﬁc serotonin receptors, there is a real possibility
for signiﬁcant advances to be made in the ﬁeld of
serotonin and the liver. These studies may ultimately
lead to new therapies that may enhance the regenera-
tive capacity of the liver, helping the many people suf-
fering from chronic liver disease.
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